Strain of Lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout
AssigneeFood Industry Research and Development Institute
InventorsSiao-Jhen Chen, Yen-Lin Chen, Hsun-Yin Hsu, Shy-Yunn Wann, Mei-Huei Chen, Li-Wen Yu
Life of this patent
Estimating the term…
Abstract
A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.
Claims10
A method for reducing uric acid levels in a subject, the method comprising culturing Lactobacillus rhamnosus in a medium to form a composition and administering the composition to a subject in need thereof in an amount effective for reducing uric acid levels, wherein the Lactobacillus rhamnosus is removed from the composition prior to the administering step.
A method for producing a composition for reducing uric acid levels in a subject, the method comprising inoculating a medium with Lactobacillus rhamnosus, culturing the Lactobacillus rhamnosus in the medium, removing the Lactobacillus rhamnosus from the medium to form a composition free of Lactobacillus rhamnosus, and lyophilizing the composition, wherein the Lactobacillus rhamnosus is Lactobacillus rhamnosus I21 deposited under Accession No. DSM 28876.
A method for producing a composition for reducing uric acid levels in a subject, the method comprising inoculating a medium with Lactobacillus rhamnosus, culturing the Lactobacillus rhamnosus in the medium, removing the Lactobacillus rhamnosus from the medium to form a composition free of Lactobacillus rhamnosus, and sterilizing the composition by pasteurization, irradiation, autoclave, or filtration, wherein the Lactobacillus rhamnosus is Lactobacillus rhamnosus I21 deposited under Accession No. DSM 28876.
Dependencies are inferred from the claim text.